IN BRIEF: Angle celebrates agreement with Recursion Pharmaceuticals

Angle PLC - Guildford, England-based liquid biopsy company - Announces it has signed an agreement ...

Alliance News 19 September, 2024 | 1:44PM
Email Form Facebook Twitter LinkedIn RSS

Angle PLC - Guildford, England-based liquid biopsy company - Announces it has signed an agreement with Recursion Pharmaceuticals Inc, a clinical-stage biotech company. It will launch with a fully-funded pilot study. Further details are confidential between the two companies.

Chief Executive Andrew Newland says: "Whilst the study is modest in size during the pilot phase, there is the potential for larger follow-on contracts in the event of a successful pilot study. Recursion has partnerships with multiple leading large pharma companies and this agreement, Angle's fourth for 2024, further builds on the expansion of our large pharma services business."

Current stock price: 11.12 pence per share, up 3.4% in London on Thursday afternoon

12-month change: down 26%

By Emily Parsons, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
ANGLE PLC 1.03 GBX 17.14 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures